-
A randomized double-blind placebo-controlled Phase 3 study of Debio 1143 in combo w/ platinum-based chemo & standard fractionation intensitymodulated radiotherapy in patients w/ locally advanced HNSCC suitable for definitive chemoradiotherapy
The purpose of the study is to compare the efficacy and safety of Debio 1143 versus matched placebo, when administered in combination with platinum-based chemotherapy ...Phase
Interventional
-
A Phase 3 Multi-center Randomized Double-blinded Study of MK-7684 with Pembrolizumab as a Co-formulation (MK-7684A) Versus Pembrolizumab Monotherapy as a First Line Treatment for Participants with PD-L1 Positive (TPS>=1%) Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to determine and compare MK-7684A to pembrolizumab alone for participants with PD-L1 Positive (TPS>=1%) Metastatic Non-Small Cell Lung ...Phase
Interventional
-
A Phase 3 Randomized Multicenter Double-Blind Placebo-Controlled Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
The purpose of the study is to evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care in Mayo ...Phase
Interventional
-
eMonarcHER: A Randomized Double Blind Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk Node-Positive HR+ HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
The purpose of the study is to determine and compare the efficacy of abemaciclib plus physician’s choice ET (endocrine therapy) versus placebo plus physician ...Phase
Interventional
-
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINAL ZONE LYMPHOMA (MZL)
The purpose of the study is to determine and investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with ...Phase
Interventional
